COVID-19: CARB-X remains open for business – virtually

CARB-X staff members are working from home. We continue to make payments to support the research programs in our portfolio, and will announce new awards as they are approved and contracts finalized.

Even as we struggle with the COVID-19 pandemic, it is critical that we continue to support the development of innovative antibiotics and other therapeutics, vaccines and diagnostics to address drug-resistant bacteria.


CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $325 million in 86 projects around the world.











focused on new classes


The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More

Spotlight on Science

Vedanta Biosciences’ new VE303 drug will prevent live-threatening C. difficile infections by boosting the body’s microbiome

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video




UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners




New London, NH

Gordon Research Conference: Structure, Dynamics and Development of Bacterial Cells


Boston, MA

World Microbe Forum



Sepsis Tech & Innovation 2021


  • 04.27.2021  |  CARB-X is funding UK-biotech GenomeKey to develop a rapid diagnostic for sepsis, a leading cause of death in hospitals full release

  • 04.20.2021  |  CARB-X is funding Baebies Inc. to develop a rapid diagnostic for neonatal sepsis full release

  • 04.19.2021  |  CARB-X is funding Phico Therapeutics to develop an engineered bacteriophage drug to treat ventilator-associated pneumonia caused by drug-resistant Pseudomonas aeruginosa full release

See All News

In The News

  • 05.05.2021  |  Mutabilis’ EBL-1463 programme graduates from ENABLE with Development Candidate and continues to progress with funding and support from CARB-X full story

  • 04.30.2021  |  Treating antibiotic resistance: Need for diagnostics and AI full story

  • 04.16.2021  |  Antibiotic pipeline offers little hope to counter ‘silent pandemic’ of superbugs, WHO warns full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.